COEPTIS THERAPEUTICS HOLDING (COEP)

In today's session, these stocks are experiencing unusual volume.

Let's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Why Is Coeptis Therapeutics Stock Falling On Friday?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares are trading lower on Friday. The firm announced plans to implement a 1-for-20 reverse stock split, which will take effect on December 31. The decision follows authorization from the company's board of directors and majority stockholders. The reverse stock split aims to help the company meet the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share, which is necessary to maintain its listing on the exchange. Also Read: 3

Which stocks are gapping on Friday?

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

These stocks are moving in today's pre-market session

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Coeptis Therapeutics Announces Reverse Stock Split

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy...

Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Let's have a look at the gap up and gap down stocks in today's session.

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell...

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024

Coeptis Therapeutics just reported results for the second quarter of 2024.

COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Coeptis Therapeutics (NASDAQ:COEP) just reported results for the second quarter...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning!

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024

Coeptis Therapeutics just reported results for the first quarter of 2024.

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023

COEP stock results show that Coeptis Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Biotech Innovation: Coeptis Therapeutics (COEP) And 3 Companies Changing The Game

Biotech Bright Spots: Coeptis Therapeutics (COEP) And 3 Hidden Treasures

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics to Present at the Emerging Growth Conference

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...